European Journal of Cancer

Publication Venue For

• 1205 Is it all about price? Why anticancer drugs do not get recommended for government subsidy in Australia 2015
• 1558 Quality of life and circulating tumour cells in patients treated with neoadjuvant chemoradiation for rectal cancer - is there a link? 2015
• 2108 Subgroup analysis by KRAS status in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression during or following first-line combination therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine 2015
• 2123 Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer 2015
• 2172 Presence of circulating tumour cells and correlation with inflammatory markers in non-metastatic rectal cancer 2015
• P0092 The rising cost of anti-cancer drugs 2014
• Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29 2014
• 32 Circulating Tumour Cells, Utility Beyond Prognosis? 2012
• 610 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma 2012
• 613 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors 2012
• 1225 POSTER A Randomised, Double-blind, Placebo Controlled, Multi-site Study of Subcutaneous Ketamine in the Management of Cancer Pain 2011
• PET and PK analysis of the humanized monoclonal anti-VEGF antibody HuMV833. An EORTC-biological treatment development group phase I study 2001
• Phase II study results on safety and efficacy of CAELYX® (DOXIL®) in combination with paclitaxel in the treatment of metastatic breast cancer 1999
• 1353 Central venous access removal in a haemato-oncology unit: A prospective audit 1997
• 1058 A phase II evaluation of bone marrow protection by ethyol® (Amifostine)(Am) in patients with non-small cell lung cancer (NSCLC) treated with carboplatin(c) 1995